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Abstract: Despite intense efforts to develop non-cytotoxic anticancer treatments, effective 
agents are still not available. Therefore, novel apoptosis-inducing drug leads that may be 
developed into effective targeted cancer therapies are of interest to the cancer research 
community. Targeted cancer therapies affect specific aberrant apoptotic pathways that 
characterize different cancer types and, for this reason, it is a more desirable type of 
therapy than chemotherapy or radiotherapy, as it is less harmful to normal cells. In this 
regard, marine sponge derived metabolites that induce apoptosis continue to be a promising 
source of new drug leads for cancer treatments. A PubMed query from 01/01/2005 to 
31/01/2011 combined with hand-curation of the retrieved articles allowed for the 
identification of 39  recently confirmed apoptosis-inducing anticancer lead compounds 
isolated from the marine sponge that are selectively discussed in this review.  
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1. Introduction 
Conventional anticancer treatment such as ionizing radiation, hyperthermia, alkylating agents, DNA 
topoisomerase inhibitors, and platinum compounds induce DNA damage indiscriminately, thus killing 
the normal cell and the rapidly proliferating cancer cell. Since these drugs are not specifically selective 
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for cancer cells, cancer patients suffer from adverse side effects [1]. These cytotoxic anticancer 
treatments are being supplemented by targeted therapies that recognize specific targets for cancer cell 
to improve efficacy of treatment and reduce side effects. Targeted therapies include apoptosis-inducers, 
angiogenesis inhibitors, signal-transduction inhibitors, monoclonal antibodies and gene therapy [2]. 
Apoptosis-inducers in particular can be used to induce cell death via the genes and proteins that control 
apoptosis, since tumor-specific alterations in apoptotic programs provide opportunities to target cell 
death in a selective manner [3]. Using these genes and proteins as potential drug targets, the   
apoptosis-inducers that directly induce apoptosis may provide less opportunity for acquired drug 
resistance, decrease mutagenesis and reduce toxicity. It is for these reasons that we have a general 
interest in identifying compounds that possess apoptosis-inducing capabilities. In the last decade 
numerous apoptosis-inducers have been isolated from marine sponges. 
Marine sponges, Phylum Porifera, are the most primitive of the multicellular organisms comprising 
approximately 15,000 sponge species [4]. Sponges are primarily filter feeders as most rely on water 
constantly circulating through their porous bodies from which they filter out microorganisms and 
organic particles as a food source, others rely on endosymbionts to produce food and oxygen [5], while 
others have also been identified as carnivores that feed mainly on small crustaceans [6]. Sponges, 
and/or their symbionts, produce a plethora of secondary metabolites to repel and deter predators [7,8] 
and to compete for space with other sessile marine organisms [9]. Sponges are acknowledged as the 
most versatile source of marine natural products with biomedical applications [10–12].  
The first successful sponge-derived pharmaceutical drugs were the nucleosides spongothymidine 
and spongouridine which were isolated from Tectitethya crypta (formerly Cryptotethya crypta) [13,14]. 
A derivative of these nucleosides, Ara-C (also known as 1-beta-D-Arabinofuranosylcytosine or 
cytarabine) is documented as the first marine derived anticancer agent [15] that is currently used for 
the treatment of leukemia [16]. Ara-C is also screened in several clinical trials for the treatment of 
acute myeloid leukemia (AML) in combination with drugs such as Daunoribicin [17], Clofarabine [18] 
and Cladribine [19].  
Despite the technological challenges in characterizing and scaling up production of bioactive 
compounds from marine sponges [20], several sponge-derived anticancer compounds are in 
preclinical/clinical trials [21–24]. Here, we review recently confirmed apoptosis-inducing anticancer 
lead compounds isolated from marine sponges which may have the potential to be future drug 
molecules. We used the National Center for Biotechnology Information (NCBI) PubMed database [25] 
to search for marine sponge derived anticancer compounds using the following keywords: 
‘marine sponge’ AND (programmed cell death OR apoptosis OR antitumor* OR anti-tumor* OR 
anticancer* OR anti-cancer* OR antineoplasm* OR anti-neoplasm*) 
This query was limited to articles published from 01/01/2005 to 31/01/2011, so as to include only 
recently confirmed apoptosis inducing lead compounds isolated from marine sponges. This yielded a 
total of 218 documents, curation of which allowed for the identification of 39 apoptosis-inducing lead 
compounds (Table 1) that have the potential to be developed as anticancer drugs. Mar. Drugs 2011, 9  
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Table 1. Recently confirmed apoptosis-inducing compounds isolated from marine sponges. 
Compound Type  Sponge  Cell  line  Reference 
(1) 2,3-dihydro-2,3-
dioxoaaptamine 
alkaloid  Aaptos sp.  THP-1 [26]  (abstract)
(2) 3-(methylamino)demethyl 
(oxy)aaptamine 
alkaloid  Aaptos sp.  THP-1 [26]  (abstract)
(3) 6-(N-morpholinyl)-4,5-
dihydro-5-oxo-demethyl 
(oxy)aaptamine 
alkaloid  Aaptos sp.  THP-1 [26]  (abstract)
(4) kuanoniamine A   alkaloid  Oceanapia sagittaria MCF-7 [27] 
(5) kuanoniamine C  alkaloid  Oceanapia sagittaria MCF-7 [27] 
(6) Makaluvic acid C  alkaloid  Strongylodesma 
aliwaliensis 
WHC01 
WHC06 
KYSE30 
[28] 
(7) Monanchocidin  alkaloid  Monanchora pulchra THP-1 
HeLa 
[29] 
(8) N-1-β-D-ribofuranosyl 
damirone C 
alkaloid  Strongylodesma 
aliwaliensis 
WHC01 
WHC06 
KYSE30 
[28] 
(9) N-1-β-D-ribofuranosyl 
makalu-vamine I 
alkaloid  Strongylodesma 
aliwaliensis 
WHC01 
WHC06 
KYSE30 
[28] 
(10) N-1-β-D-ribofuranosyl 
makaluvic acid C 
alkaloid  Strongylodesma 
aliwaliensis 
WHC01 
WHC06 
KYSE30 
[28] 
(11) Naamidine A  alkaloid  Leucetta chagosensis A-431 [30] 
(12) Psammaplysene A  alkaloid  Psammaplysilla  Ishikawa ECC1  [31] 
(13) Renieramycin M  alkaloid  Xestospongia sp.  NSCLC [32] 
(14) Bastadin 6  alkaloid  lanthella sp.  HUVEC [33]  (abstract)
(15) (Z)-stellettic acid C  lipid  Stelletta sp.  U937 [34]  (abstract)
(16) 5-alpha,6-alpha-epoxy-
petrosterol 
lipid  Lanthella sp.  HL-60 [35] 
(17) Callyspongidiol  lipid   Callyspongia sp.  HL-60 [36]  (abstract)
(18) Jaspine B  lipid  Jaspis sp.  SK-Mel28 [37] 
(19) Petrosterol  lipid  Lanthella sp.  HL-60 [35] 
(20) Petrosterol-3,6-dione  lipid  Lanthella sp.  HL-60 [35] 
(21) Rhizochalin  lipid  Rhizochalina 
incrustata 
THP-1 HeLa 
SNU-C4 
[38] 
(22) Candidaspongiolide  macrolide Candidaspongia sp.  U251 
HCT116 
[39] 
(23) Irciniastatin A  macrolide Ircinia ramose  Jurkat T  [40] 
(24) Latrunculins A and B  macrolide Negombata 
magnifica 
MKN45 
NUGC-4 
[41] (abstract)
(25) Salarin C  macrolide Fascaplysinopsis sp.  K562 [42] 
(26) Spongistatin 1  macrolide Spongia  Jurkat T  [43] Mar. Drugs 2011, 9  
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Table 1. Cont. 
(27) 13E,17E-globostellatic 
acid X methyl ester 
terpenoid Rhabdastrella 
globostellata 
HUVEC [44] 
(28) 3-epi-sodwanone K  
3-acetate 
terpenoid Axinella sp.  T47D [45] 
(29) Geoditin A  terpenoid Geodia japonica  HL-60 
HT29 
[46] 
[47] 
(30) Geoditin B  terpenoid Geodia japonica  HL-60 [46] 
(31) Heteronemin  terpenoid Hyrtios sp.  K562 
Jurkat T 
[48] 
(32) Ilimaquinone  terpenoid Hippospongia 
metachromia 
PC3 [49] 
(33) Jaspolide B  terpenoid Jaspis sp.  Bel-7402 
HepG2 
[50] 
(34) Rhabdastrellic acid-A  terpenoid Rhabdastrella 
globostellata 
HL-60 [51] 
(35) Sipholenol A  terpenoid Callyspongia 
siphonella 
KB-3-1 
KB-C2 
KB-V1 
[52] 
(36) Smenospongine  terpenoid Dactylospongia 
elegans 
K56 [53] 
(37) Sodwanone V  terpenoid Axinella sp.  MDA-MB-231 [45] 
(38) Stellettin A  terpenoid Geodia japonica  HL-60 [46] 
(39) Stellettin B  terpenoid Geodia japonica  HL-60 [46] 
2. Extensively Studied Apoptotic Pathways 
2.1. The Death Receptor or “Extrinsic” Apoptosis Pathway of Type I and Type II 
The extrinsic apoptosis signaling pathway is mediated by the activation of cell surface receptors 
(death receptors) that ligate with specific ligands to form a death inducing signaling complex (DISC) 
that transmits the apoptotic signals. Some DISC include CD95/Fas (CD95L/FasL) [54], TNFR1   
(TNF) [55], DR3 (Apo3L) [56], DR4 (TRAIL-R1) [57] and DR5 (TRAIL-R2) [57]. The procaspase-8 
is then sequestered by the DISC resulting in high local concentrations of zymogen. Under this 
condition, the low intrinsic protease activity of pro-caspase-8 is sufficient to allow various proenzyme 
molecules to mutually cleave and activate each other resulting in active caspase-8 [58]. Active 
caspase-8 then directly activates downstream effector caspase-3 resulting in the death of cells 
classified as type I cells (Figure 1) [59]. 
In type II cells, the above described signal requires amplification by the simultaneous activation of 
the mitochondria-dependent apoptotic pathway [59]. The mitochondria-dependent apoptotic pathway 
is activated when active caspase-8 additionally cleaves Bid to form the truncated Bid (tBid) which 
translocates to the mitochondria to induce outer membrane permeabilization whilst the inner 
membrane permeabilization that is promoted by the mitochondrial permeability transition pore formed 
across inner membranes when Ca
2+ reaches a critical threshold [60,61]. Permeabilization of the Mar. Drugs 2011, 9  
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membrane leads to the release of apoptogenic factors including cytochrome c [62], apoptosis-inducing 
factor (AIF) [63], second mitochondria-derived activator of caspases (Smac/Diablo) [64], EndoG [65] 
and HtrA2/Omi [66]. Cytochrome c and Smac/DIABLO activates the caspase dependent pathway. The 
cytochrome c disrupts the binding between Bcl-2 and pro-apoptotic protease activating factor (Apaf-1). 
The unbound Apaf-1 binds to procaspase-9 form the Apaf-1/caspase-9 complex that together with ATP 
and cytochrome c  forms the apoptosome [67]. The apoptosome activates caspase-3 and -7 [68]. 
Caspase-3 successively mediated cleavage of (1) inhibitor caspase-activated deoxyribonuclease IFN 
(ICAD) resulting in the release and activation of the catalytic subunit CAD which is responsible for the 
fragmentation of the DNA into approximately 200 bp fragments [69], and (2) poly (ADP-ribose) 
polymerase (PARP) [70] and caspase-6 [71]; thus impeding the DNA repair mechanism, and bringing 
forth lamin protein degradation along with the disturbance of the fodrin and gelsolin matrix 
respectively [72,73]. Smac/DIABLO aids the caspases in dismantling of the cell by binding to and 
deactivating the inhibitor of apoptosis proteins (IAPs), thus preventing the IAPs from arresting the 
apoptotic process [74]. The other apoptogenic factors such as AIF and Endo G promotes DNA 
fragmentation in a caspase-independent manner to execute cell death [65,75]. AIF additionally induces 
the negatively charged phosphatidylserine to externalize on the cell membrane [76]. HtrA2/Omi is a 
Smac/DIABLO-like inhibitor of IAP activity that acts in a caspase-independent manner to execute cell 
death [66]. As a consequence of the above sequence of events, apoptotic cells display characteristic 
morphology changes such as cellular shrinking, chromatin condensation and margination at the nuclear 
periphery which ultimately results in membrane-bound apoptotic vesicles that are phagocytosed 
without triggering inflammatory responses that are distinct from that seen with necrotic cells [77]. 
Figure 1. Schematic illustration of the death receptor (type I and type II) and 
mitochondrial pathways. 
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2.2. The Mitochondrial or “Intrinsic” Apoptosis Pathway 
The mitochondrial pathway can be activated by a variety of receptor-independent stimuli such as 
radiation, chemotherapeutics, hypoxia, ROS, Bax, p53 and viral infections [78]. Exposure to radiation 
or chemotherapeutics induces DNA damage that leads to the activation of p53 [79]. Activated p53 
initiated the expression of (1) p21 that binds to the cyclin/kinase complex giving rise to a cell cycle 
restriction site in which an attempt is made to repair the DNA, and (2) GADD + PCNA that attempts to 
repair the DNA damage. If the DNA damage is irreparable p53 further initiated the expression of the 
Bax [80]. The increased levels of Bax increase the concentrations of Bax/Bax complexes (proapoptotic 
complex) that have been demonstrated to displace the Bcl-2/Bax complexes (anti-apoptotic complex) 
that compete for the same receptor site on the mitochondrial membrane [81]. The binding of the 
Bax/Bax complex to the mitochondrial membrane brings forth the release of the apoptogenic factors 
that signifies the point where the intrinsic and extrinsic pathways converge (refer to Figure 1). 
3. Apoptosis-Inducing Lead Compounds 
An overview of the 39 apoptosis-inducing lead compounds from marine sponge reported in literature 
since 01/01/2005, based on their putative biogenetic origin is presented in Figure 2. The compounds 
identified comprised 14 alkaloids, 13 terpenoids, 7 lipids and 5 macrolides. The disproportionately 
high frequency of alkaloids and terpenoids was also observed by Blunt et al. (2008) [82]. 
Figure 2. Recently confirmed apoptosis-inducing lead compounds isolated from marine 
sponge since the 01/01/2005, divided by putative biogenetic origin. 
 
3.1. Alkaloids 
3.1.1. Renieramycin M 
Renieramycins are members of the tetrahydroisoquinoline family that were isolated from   
marine sponges belonging to genera Reniera [83], Xestospongia [84,85], Cribrochalina [86] and 
Neopetrosia [87]. A recent study by Halim et al. demonstrated that Renieramycin M (Figure 3) 
isolated from the Xestospongia species induced apoptosis via the p53-dependent pathway and inhibits 
the progression and metastasis of non-small lung cancer cells [32]. Other members of this family such Mar. Drugs 2011, 9  
 
 
1586
as Renieramycin G and its analog 3-epi-renieramycin G, both of which possess an amide carbonyl 
group at the C-21 position demonstrated minimal antiproliferative activity in human colorectal cancer 
(HCT-116) and human lung adenocarcinoma (A549) cells owing to both compounds possessing an 
amide carbonyl group at the C-21 position [88]. The minimal antiproliferative activity for members of 
the tetrahydroisoquinoline family possessing an amide carbonyl group at the C-21 position seems 
consistent compared to their C-21 cyano- or carbinolamine-containing relatives [89].  
Figure 3. Structure of Renieramycin M. 
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3.1.2. Naamidine A 
Copp et al. isolated Naamidine A (Figure 4) from the Fijian marine sponge Leucetta chagosensis 
and demonstrated that the compound inhibits the EGF signaling pathway and is more specific for the 
EGF-mediated mitogenic response than for the insulin-mediated mitogenic response [90]. In 2009, 
LaBarbera et al. demonstrated that Naamidine A induces biomarkers of apoptosis such as 
externalization of phosphatidylserine, disruption of the mitochondrial membrane potential, and 
cleavage and activation of caspases-3, -8, and -9, suggesting that the cell death induced by Naamidine 
A in epidermoid carcinoma (A-431) cells is a result of apoptosis rather than cytotoxicity [30]. 
Naamidine A was also shown to inhibit tumour xenograft growth via activation of caspase-3 
suggesting apoptosis activity in vivo. Furthermore, Naamidine A-induced apoptosis is independent of 
extracellular signal-regulated kinase 1/2 and does not require functional p53 [30]. 
Figure 4. Structure of Naamidine A. 
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3.1.3. Psammaplysene A 
Schroeder et al. (2005) isolated Psammaplysene A and B (Figure 5) from the Indian Ocean marine 
sponge, Psammaplysilla sp. when screening for specific inhibitors of nuclear export of the transcription 
factor FOXO1a [91]. Schroeder et al. demonstrated that both Psammaplysene A and B were   
active inhibitors of FOXO1 nuclear export but Psammaplysene A was the more potent inhibitor [91]. 
Berry et al. further demonstrated that human endometrial cancer (Ishikawa and ECC-1) cells treated 
for 24 h with 1 μΜ Psammaplysene A induces cell death displaying morphology changes consistent 
with apoptosis and PARP cleavage, suggesting that the cell death induced by Psammaplysene A   
is a consequence of apoptosis rather than cytotoxicity. Psammaplysene A was also shown to   
induce the doubling of cells in the G2/M phase and FOXO1 silencing in ECC-1 cells lessens   
Psammaplysene A-induced apoptosis [31]. 
Figure 5. Structure of Psammaplysene A. 
3
 
3.1.4. Monanchocidin 
Monanchocidin (Figure 6) is a novel polycyclic guanidine alkaloid isolated from the marine sponge 
Monanchora pulchra [29]. Guzii et al. demonstrated that Monanchocidin induces cell death in human 
monocytic leukemia (THP-1), human cervical cancer (HeLa) and mouse epidermal (JB6 Cl41) cells. 
Additionally, they demonstrated that THP-1 cells treated for 12 h with 1 μΜ Monanchocidin induces 
externalization of phosphatidylserine, suggesting that cell death induced by Monanchocidin may be a 
consequence of apoptotic as opposed to necrotic cell death [29]. 
Figure 6. Structure of Monanchocidin. 
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3.1.5. Kuanoniamines A and C 
Kuanoniamines A and C (Figure 7), pyridoacridine alkaloids isolated from the Thai marine sponge 
Oceanapia sagittaria were shown to be growth inhibitors of breast adenocarcinoma (estrogen-dependent 
ER (+)) (MCF-7), breast adenocarcinoma (estrogen-independent ER (−)) (MDA-MB-231), non-small 
cell lung cancer (NCI-H460), diploid embryonic lung fibroblast (MRC-5), glioblastoma (SF-268) and 
melanoma (UACC-62) cells [27]. Kuanoniamine C was less potent but showed high selectivity toward 
the estrogen dependent (ER+) MCF-7 cells. It was further demonstrated that Kuanoniamine A is a 
more potent inhibitor of DNA synthesis than Kuanoniamine C, and Kuanoniamine A was shown to 
cause an extensive reduction of the MCF-7 cells in the G2/M phase. It was also demonstrated that 
MCF-7 cells treated for 24 h with Kuanoniamine A (0.5 and 1 μΜ) and Kuanoniamine C (1 and 
2.5 μΜ) respectively, displayed DNA fragmentation consistent with apoptosis [27]. Interestingly, in 
1994, MacDonald et al. isolated the congeners Dehydrokuanoniamine B and Kuanoniamine D from 
the Fijian Cystodytes sp. ascidian and demonstrated that these compounds inhibit TOPO II-mediated 
decatenation of kinetoplast DNA correlated with their cytotoxic potencies and their ability to 
intercalate into calf thymus DNA [92]. Taken together, Kuanoniamines A and C likely inhibit DNA 
synthesis via the same mechanism as Dehydrokuanoniamine B and Kuanoniamine D. 
Figure 7. Structure of Kuanoniamines A (1) and C (2). 
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3.2. Terpenoids 
3.2.1. Rhabdastrellic Acid-A 
In 1997, Rao et al. isolated Rhabdastrellic acid-A (Figure 8), a novel triterpenoid from the marine 
sponge  Rhabdastrella globostellata. Ten years later, Guo et al. demonstrated that human 
promyelocytic leukemia (HL-60) cells treated for 36 h with 1 μM Rhabdastrellic acid-A induces 
condensation of nuclear chromatin and DNA fragmentation. Rhabdastrellic acid-A was also shown to 
induce other hallmarks of apoptosis such as PARP cleavage and caspase-3 activation [51]. They 
additionally demonstrated that mRNA levels of 44 genes, including p73, JunD, TNFAIP3   
and GADD45A, were up-regulated whilst the mRNA levels of 16 genes, including MAP2K5 and 
IGF2R, were down-regulated [50]. Li et al. demonstrated that Rhabdastrellic acid-A also induces 
caspase-independent autophagy-associated cell death through blocking the Akt pathway in 
heptocellular carcinoma (Hep3B) and A549 cells [93]. Mar. Drugs 2011, 9  
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Figure 8. Structure of Rhabdastrellic acid-A. 
 
Li et al. further isolated nine new isomalabaricane-derived natural products, Globostelletins A–I 
from the marine sponge Rhabdastrella globostellata, together with Jaspolides F, Rhabdastrellic acid-A, 
(−)-Stellettin E, Stellettins C and D [94]. They demonstrated that all the compounds induced inhibitory 
activities in A549, human gastric gland carcinoma (BGC-823), human intestinal adenocarcinoma 
(HCT-8) and human hepatocellular carcinoma (Bel-7402) cells and confirmed that HL-60 cells treated 
for 24 h with 5 μM Rhabdastrellic acid-A induces externalization of phosphatidylserine characteristic 
of apoptotic cell death [94].  
3.2.2. Stellettin A and B, and Geoditin A and B 
Zhang and Che isolated four isomalabaricane triterpenes (Stellettin A, Stellettin B, Geoditin A and 
Geoditin B) (Figure 9) from marine sponge Geodia japonica [95]. Liu et al. demonstrated that 
Stellettin A, Stellettin B, Geoditin A and Geoditin B induce cytotoxicity in HL-60 cells with Geoditin 
A being the most potent, followed by Stellettin A and B while Geoditin B showed the least potency.  
Liu et al. further demonstrated that HL-60 cells treated for 24 h with 3 μM of all four compounds 
respectively, induced dissipation of mitochondrial membrane potential, activation of caspase-3, and a 
decrease in levels of proliferating cell nuclear antigen (PCNA) characteristic of apoptotic cell death [46]. 
It was also demonstrated that apoptosis induced by Geoditin A displayed a dose-dependent increase of 
reactive oxygen species (ROS) and an increase in externalization of phosphotydilserine [46]. 
Figure 9. Structure of Stellettin A (1) and B (2), and Geoditin A (3) and B (4). 
(1) (2)
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Figure 9. Cont. 
(3) (4)
 
3.2.3. Jaspolide B 
Jaspolide B (Figure 10), a novel isomalabaricane-type triterpene was isolated from the sponge 
Jaspis sp. [50,96]. Wei et al. demonstrated that Bel-7402 and human hepatocellular liver carcinoma 
(HepG2) cells treated for 24 h with 20 μM Jaspolide B induces increased mitochondrial masses and 
cell membrane permeability, as well as nuclear condensation characteristic of apoptotic cell death. 
Jaspolide B was also shown to induce cell cycle arrest in the G1 phase in both Bel-7402 and HepG2 
cells [50]. Moreover, Jaspolide B induced disassembly of the microtubule cytoskeleton in Bel-7402 
cells, the effect of which being similar but weaker than that of the known microtubule-disassembly 
agent, colchicines [50]. 
Figure 10. Structure of Jaspolide B. 
 
3.2.4. Smenospongine 
Kondracki and Guyot were the first to isolate Smenospongine (Figure 11) from the Smenospongia sp. 
as early as 1987 and demonstrated that Smenospongine induces cytotoxic and antimicrobial activity [97]. 
Later, Aoki et al. isolated Smenospongine from the Indonesian marine sponge Dactylospongia  
elegans [44,98]. It was demonstrated that Smenospongine induced the differentiation of human 
erythromyeloblastoid leukaemia (K562) cells into erythroblasts, cell-cycle arrest in the G1 phase and Mar. Drugs 2011, 9  
 
 
1591
increased expression of p21 [98]. In addition, human leukemic monocyte lymphoma (U937) cells 
treated for 24 h with 15 μM Smenospongine induced DNA fragmentation characteristic of apoptotic 
cell death [53]. Kong et al. further demonstrated that smenospongine-induces antiproliferative and 
antiangiogenic activities such as endothelial migration and tube formation of human umbilical vein 
endothelial cells (HUVECs) [99]. 
Figure 11. Structure of Smenospongine. 
2
 
3.2.5. 13E,17E-Globostellatic Acid X Methyl Ester 
Aoki et al. isolated seven new compounds (13Z,17Z-globostellatic acid X methyl ester,   
13Z,17E-globostellatic acid X methyl ester, 13E,17Z-globostellatic acid X methyl ester, and   
13E,17E-globostellatic acid X methyl ester (Figure 12), Acetyljaspiferal E, Globostellatic acid F 
methyl ester and 13E-globostellatic acid B methyl ester) from the marine sponge Rhabdastrella 
globostellata, as selective anti-proliferative agents of HUVECs [44]. They demonstrated that HUVECs 
treated for 48 h with 1 μΜ 13E,17E-Globostellatic acid X methyl ester induces caspase-3 and -7 
activity, suggesting that 13E,17E-globostellatic acid X methyl induced cell death may be a 
consequence of apoptosis [44]. Aoki et al. further demonstrated that 13E,17E-Globostellatic acid X 
methyl ester also induces antiangiogenic activities such as endothelial migration and tube formation of 
HUVECs [44]. 
Figure 12. Structure of 13E,17E-globostellatic acid X methyl ester. 
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3.3. Lipids 
3.3.1. Petrosterol-3,6-dione and 5α,6α-epoxy-Petrosterol 
Nguyen et al. isolated two new C29 sterols, Petrosterol-3,6-dione and 5α,6α-epoxy-petrosterol 
(Figure 13) along with the known C29 sterol, Petrosterol from the Vietnamese marine sponge   
Ianthella sp. [35]. It was shown that all three compounds induced cell death in A549, HL-60, U937, 
MCF-7 and human ovarian carcinoma (SK-OV-3) cells. To further evaluate whether this cell death 
was necrotic or apoptotic, the HL-60 cells were treated for 24 h with IC50 (19.9, 21.3, and 21.5 μΜ) of 
each compound (Petrosterol-3,6-dione, 5α,6α-epoxy-petrosterol and Petrosterol) respectively. Each 
compound induced apoptotic events such as chromatin condensation and DNA fragmentation with 
Petrosterol being the more potent apoptosis inducer [35]. Since the compounds induced apoptotic cell 
death in HL-60 cells, it is expected to be able to induce apoptotic cell death in the other cells tested but 
which compound will be the most potent in the other cell lines and the mechanisms of cell death 
induced by these compounds based on cancer cell types remains unresolved. 
Figure 13. Structure of Petrosterol-3,6-dione (1) and 5α,6α-epoxy-petrosterol (2). 
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3.3.2. Pachastrissamine 
Kuroda et al. originally isolated the anhydrophytosphingosine, Pachastrissamine (also known as 
Jaspine B) (Figure 14) from the marine sponge Pachatrissa sp. and demonstrated that Pachatrissamine 
induced cytotoxicity in mouse lymphocytic leukemia (P388), A-549, human colon adenocarcinoma  
(HT-29) and human melanoma (SK-Mel-28) cells [100]. Salma et al. further demonstrated that B16 
mouse melanoma cells induced for 6 h with 5 μM Pachastrissamine trigger hallmarks of apoptosis such 
as externalization of phosphatidylserine, release of cytochrome c, PARP cleavage and activation of 
caspase-3 and -9. Moreover, they demonstrated that Pachastrissamine inhibited the activity of 
sphingomyelin synthase (SMS), an enzyme that converts ceramide into the membrane lipid 
sphingomyelin. To evaluate whether this inhibitory activity played a role in the Pachastrissamine-induced 
cell death mechanism, they further demonstrated that cell death was enhanced in SMS1-depleted cells, 
whilst it was strongly inhibited in cells that stably overexpress human SMS1 [37]. Taken together, 
ceramide formation plays a key role in activating the mitochondrial-dependent pathway induced   
by Pachastrissamine. Mar. Drugs 2011, 9  
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Figure 14. Structure of Pachastrissamine. 
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3.3.3. Rhizochalin 
Rhizochalin (Figure 15) is a two-headed sphingolipid isolated from the Madagascarian sponge 
Rhizochalin incrustata [101]. Jin et al. demonstrated that HL-60 cells induces for 24 h with 10 μM 
Rhizochalin display hallmarks of apoptosis such as disruption of the mitochondrial membrane 
potential, cleavage of PARP and activation of caspase-3, -8 and -9 in HL-60 cells [102]. The activation 
of caspase-8 suggests that this two-headed sphingolipid induces a death receptor pathway. 
Figure 15. Structure of Rhizochalin. 
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3.4. Macrolides 
3.4.1. Salarin C 
Ben-Califa et al. isolated Salarin A–J from the marine sponge Madagascar Fascaplysinopsis sp. and 
demonstrated that Salarin C (Figure 16) is the most potent proliferation inhibitor of K562 cells [42]. It 
was further shown that K562 cells induced for 24 h with 0.1 μΜ Salarin C-displayed numerous 
hallmarks of apoptosis such as externalization of phosphotydilserine, cleavage of PARP and activation 
of caspase-3 and -9 [42].  
Figure 16. Structure of Salarin C. 
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3.4.2. Spongistatin 1 
The macrocyclic lactone polyether Spongistatin 1 (Figure 17) was isolated as early as 1993 from the 
marine sponge Spongia sp. [103,104]. Spongistatin 1 was shown to inhibit mitosis, microtubule 
assembly, and the binding of vinblastine to tubulin thereby inducing cytotoxic cell death in numerous 
cancer cell lines [104]. Fifteen years later, Schyschka et al. demonstrated that Spongistatin 1-induced 
human acute leukemia (Jurkat T) cells displayed hallmarks of apoptosis such as mitochondrial-released 
of cytochrome c, Smac/DIABLO and Omi/HtrA2 and caspase activation [43]. The activation of 
caspase-9 and suppression of Spongistatin 1-induced apoptosis by overexpressed Bcl-2 and Bcl-xL 
indicates that Spongistatin 1-induces apoptosis through the mitochondrial pathway. Moreover, 
Spongistatin 1 was shown to degrade XIAPs and induce cell death in leukemic tumor cells that are 
known to be resistant to apoptosis induction due to the overexpression of XIAPs [43]. 
Figure 17. Structure of Spongistatin 1. 
 
Schneiders et al. additionally demonstrated that MCF-7 cells treated for 8 h with 500 pM 
Spongistatin 1 displayed activation of Bim and by 16 h Bim had mediated the translocation of   
AIP and endo G from the mitochondria. They further used gene silencing to confirm that the 
Spongistatin 1-induced apoptosis is primarily via a caspase-independent signaling pathway [105] 
Rothmeier et al. further demonstrated that Spongistatin 1 is a microtubule-depolarizing compound that 
induces endothelial migration, tube formation, G2/M arrest, and induction of apoptosis at roughly the 
same inhibitory concentration (1 nM) [106]. Spongistatin 1 was demonstrated to be a more potent 
inhibitor of angiogenesis than Vinblastine, CA4P, and Paclitaxel, as Spongistatin 1-induced proliferation 
100 pM, migration 1.0 nM, tube formation 1.0 nM, chemotaxis 1.0 nM and aortic ring sprouting 500 pM. 
3.4.3. Candidaspongiolide 
Meragelman et al. isolated Candidaspongiolide (Figure 18) from the marine sponge 
Candidaspongia sp. and demonstrated that this compound induced potent cytotoxicity in melanoma 
and glioma cells [107]. Trisciuoglio et al. further demonstrated that HCT-116 and human glioblastoma 
(U251) cells treated for 24 h with 50 μM Candidaspongiolide induced hallmarks of apoptosis such as Mar. Drugs 2011, 9  
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cleavage of PARP and activation of caspase-3 and -12. They further demonstrated that 
Candidaspongiolide induced a non-classic PKR/eIF2alpha/caspase-12-dependent apoptotic pathway 
and inhibited protein synthesis in HCT-116 and U251 cells [39]. While in normal fibroblasts 
Candidaspongiolide only inhibited protein synthesis [39]. 
Figure 18. Structure of Candidaspongiolide. 
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3.4.4. Irciniastatin A 
Irciniastatin A (also known as Psymberin) (Figure 19) was isolated by Pettit et al. from the marine 
sponge Ircinia ramose [108], and by Cichewicz et al. from the marine sponge Psammocinia sp. [107]. 
Cichewicz et al. demonstrated that Irciniastatin A induced cytotoxicity in human lung melanoma 
(MALME-3M), human skin melanoma (SK-MEL-5), p53 wild-type human melanoma (UACC-62), 
HCT-116 and human breast adenocarcinoma (MDA-MB-435) cells [109]. Chinen et al. further 
demonstrated that Jurkat T cells treated for 3 h with 10 nM Irciniastatin A induced hallmarks   
of apoptosis such as capase-8, -9 and -3, suggesting that Irciniastatin A induces a death receptor 
pathway [40]. 
Figure 19. Structure of Irciniastatin A. 
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4. Discussion 
Because of the pressing need to develop non-cytotoxic anticancer treatments, novel   
apoptosis-inducing drug leads that have the potential to be developed into effective targeted cancer 
therapies are of interest to the cancer research community. In this regard, marine sponge-derived 
bioactive metabolites continue to be one of the most promising sources of new drug leads. The   
Blunt et al. yearly reviews of literature published for marine natural products covered 5666 novel 
compounds isolated from 2002 to 2008, with approximately one third of these compounds being 
isolated from marine sponge [82,110–115]. Many of these sponge-derived novel compounds have been 
screened for cytotoxic activity, but not apoptosis [116–118]. Mar. Drugs 2011, 9  
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Cytotoxic activity is regarded as the first indicator in identifying anticancer drugs [119]. However, 
increasing evidence has shown that cell death can be induced via three different mechanisms: 
apoptosis (programmed cell death type I), autophagy (programmed cell death type II, or lysosomal cell 
death), and oncosis (programmed cell death type III, also referred to as necrosis) [120]. Cell death by 
autophagy is characterized by: (a) being mainly caspase-independent; (b) organelles degrading at an 
early stage of cell death; (c) the cytoskeleton remaining preserved until the final phase of the dying 
process; and (d) the formation of autophagosomes that fuse together with lysosomes which degrade the 
autophagosomes content [120]. Marine sponge derived cytotoxic compounds such as the aminosteroid 
clionamine A [121], the alkaloid xestospongin B [122] and the triterpenoid rhabdastrellic acid-A [93] 
were shown to induce cell death by autophagy. Oncosis is characterized by: (a) cellular swelling; and 
(b) cell membrane bursting that releases the cellular contents into the environment causing inflammatory 
cell suicide [120]. In contrast with autophagy and oncosis, apoptosis is the natural cell death mechanism 
that is characterized by: (a) chromatin condensation; (b) nuclear fragmentation and chromosomal DNA 
fragmentation (karyorrhexis); (c) alterations of the cellular membrane; (d) cellular shrinkage; and 
(e) the formation of vesicles that are phagocytosed by macrophages leading to non-inflammatory cell 
suicide [120]. The mechanisms through which lead compounds induce apoptosis remains debatable; 
however, cell death via apoptosis induction is widely accepted as an effective strategy for the 
identification of potential anticancer drugs.  
The efficacy of treatment with apoptotic drugs is however limited by their toxicity to normal   
cells [123]. One of the recently confirmed apoptosis-inducing lead compounds isolated from marine 
sponges, Candidaspongiolide was shown to induce a PKR/eIF2alpha/caspase 12-dependent apoptotic 
pathway in HCT-116 and U251 cells, but not in normal fibroblasts [39].  
The apoptotic pathway induced and the structure of the apoptosis-inducing lead compound allow 
for the targeting of selective cancer types. Irciniastatin A in particular, was shown to induce selective 
cell killing against melanoma (MALME-3M, SK-MEL-5 and UACC-62), colon (HCT-116) and breast 
(MDA-MB-435) cancer cells [109]. Also, the similarly structured Kuanoniamines A and C induced 
selective cell killing against breast (MCF-7 and MDA-MB-231), lung (NCI-H460 and MRC-5), 
glioblastoma (SF-268) and melanoma (UACC-62) cancer cells [27], with Kuanoniamine C inducing 
less potent cell death than Kuanoniamines A but displaying high selectivity toward the estrogen 
dependent (ER+) breast (MCF-7) cancer cells [27]. It was also shown that a caspase-dependent 
apoptotic pathway is induced in the HL-60 cells by the similarly structured isomalabaricane triterpenes 
(Stellettin A, Stellettin B, Geoditin A and Geoditin B) [46]. Apoptosis-induction varies among these 
four isomalabaricane triperpenes, with Geoditin A being the most effective inducer, followed by 
Stellettin A, Stellettin B and Geoditin B, respectively [46]. However, it remains unclear whether there 
is a difference in the apoptosis pathways and the potency of apoptosis induced by the isomalabaricane 
triperpenes, and which compound type is a more suitable candidate lead compound to be developed 
into an anticancer drug that targets leukemia.  
Other compounds such as Rhabdastrellic acid-A has been shown to induce different types of cell 
death, as it was demonstrated that Rhabdastrellic acid-A induced caspase-dependent apoptosis in HL-60 
cells [51], but to the contrary, induces caspase-independent autophagy-associated cell death through 
blocking the Akt pathway in Hep3B and A549 cells [93].  Mar. Drugs 2011, 9  
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Having an understanding of the apoptotic mechanism induced by the lead compound and the 
advantages and the limitations of the compound structure on different cancer types will increase the 
lead compounds chances of developing into a recognized targeted cancer therapy. Furthermore, if it 
were only a matter of bioactivity, or having a unique pharmacological profile, hundreds of   
sponge-derived compounds would enter drug development in the pharmaceutical industry. However, 
other factors besides bioactivity such as a cost-effective source of large-scale supply, and drug ability 
will determine whether the lead compound enters the drug development pipeline [20]. Sponge-derived 
compounds that are currently in clinical trials were all found to be amenable to cost-effective   
chemical synthesis, thus solving the supply question early-on in the development continuum [124–126].  
Thus far, the chemical synthesis of the apoptosis-inducing lead compounds listed in Table 1   
include Renieramycin M [127], Naamidine A [128], Psammaplysenes A and B [129],   
13E,17E-globostellatic acid X methyl ester [130], Pachastrissamine [131,132], Spongistatin 1 [133,134] 
and Irciniastatin A [135,136]. 
5. Conclusions 
This review highlights recently confirmed apoptosis-inducing compounds isolated from marine 
sponge that have the potential to be developed into targeted cancer therapies. There are numerous 
cytotoxic metabolites that have been isolated from marine sponge but have not been screened for 
apoptosis activity. Moreover, the effects of the apoptosis-inducing compounds on the apoptotic 
signaling pathways have been summarized, even though most of these compounds have not yet been 
studied in depth for their mechanisms of action. Further research needs to be focused on clarifying the 
apoptotic pathways induced by the potential anticancer drugs to help singling out those that are the 
most promising for development of new anticancer drugs. 
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